Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-62 for Hypercortisolism from Benign Adrenal Tumors
NCT05436639Phase 2Completed
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of clofutriben in Autonomous Cortisol Secretion (ACS), ACTH-independent Cushing syndrome, sponsored by Sparrow Pharmaceuticals. Started Jul 2023; status: completed.
02
Drugs
clofutriben
03
Conditions
Autonomous Cortisol Secretion (ACS)ACTH-independent Cushing syndrome
Beyond the preview
Go deeper on NCT05436639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436639.